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Background: Overexpression of cyclooxygenase-2 (COX-2) has been implicated in oncogenesis and progression of
adenocarcinomas of the pancreatic head. The data on the prognostic importance of COX expression in these
tumours is inconsistent and conflicting. We evaluated how COX-2 overexpression affected overall postoperative
survival in pancreatic head adenocarcinomas.
Methods: The study included 230 consecutive pancreatoduodenectomies for pancreatic cancer (PC, n = 92),
ampullary cancer (AC, n = 62) and distal bile duct cancer (DBC, n = 76). COX-2 expression was assessed by
immunohistochemistry. Associations between COX-2 expression and histopathologic variables including degree
of differentiation, histopathologic type of differentiation (pancreatobiliary vs. intestinal) and lymph node ratio
(LNR) were evaluated. Unadjusted and adjusted survival analysis was performed.
Results: COX-2 staining was positive in 71% of PC, 77% in AC and 72% in DBC. Irrespective of tumour origin,
overall patient survival was more favourable in patients with COX-2 positive tumours than COX-2 negative (p = 0.043 in
PC, p = 0.011 in AC, p = 0.06 in DBC). In tumours of pancreatobiliary type of histopathological differentiation, COX-2
expression did not significantly affect overall patient survival. In AC with intestinal differentiation COX-2 expression
significantly predicted favourable survival (p = 0.003). In PC, COX-2 expression was significantly associated
with high degree of differentiation (p = 0.002). COX-2 and LNR independently predicted good prognosis in a
multivariate model.
Conclusions: COX-2 is overexpressed in pancreatic cancer, ampullary cancer and distal bile duct cancer and
confers a survival benefit in all three cancer types. In pancreatic cancer, COX-2 overexpression is significantly
associated with the degree of differentiation and independently predicts a favourable prognosis.Background
Primary adenocarcinomas located in the pancreatic head
arise from the ampulla, the distal bile duct, or the pancre-
atic ductal structures. Due to the topological proximity of
these structures, resectable adenocarcinomas arising from
any of these three anatomical locations are typically
resected by the same surgical procedure, i.e. curative-
intent pancreatoduodenectomy. The considerable vari-
ation in reported frequencies for the individual tumour* Correspondence: ewa.pomianowska@medisin.uio.no
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article, unless otherwise stated.sites suggests that the precise tumour origin may be dif-
ficult to determine [1] and that the applied methods for
histopathological determination of the cancer origin varies
widely among institutions [2]. Adenocarcinomas from all
three locations may be of pancreatobiliary or intestinal
type of differentiation [3].
Overexpression of cyclooxygenase-2 (COX-2) has been
described in several tumours, including colon, stomach,
breast, lung, and urinary bladder [4-16]. The COX-2 ex-
pression is a component of the cellular response to in-
flammation and is induced by several extracellular or
intracellular stimuli, including proinflammatory cyto-
kines, infectious agents, mitogens, hormones and growth
factors [17,18]. Several studies have reported overexpres-
sion of COX-2 in subsets of pancreatic adenocarcinomasentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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creased COX-2 expression has also been demonstrated
in pancreatic intraepithelial neoplasias (PanINs) [27-30].
However there is relatively few data on COX-2 expres-
sion in the two other types of pancreatic head adenocar-
cinomas, ampullary cancer [31-33] and distal bile duct
cancer [34]. Data on prognostic relevance of COX-2
overexpression in all these tumours has been inconsist-
ent and conflicting although most reports indicate an in-
verse relationship between COX-2 overexpression and
survival rates in pancreatic cancer [19,21] and ampullary
cancer [32].
The aim of the present study was to examine the prog-
nostic relevance of COX-2 expression in adenocarcinomas
from the three separate anatomical sites of origin in the
pancreatic head. The data shows that COX-2 is overex-
pressed in all three types of pancreatic head adenocarcin-
omas and that COX-2 overexpression is associated with
better survival. In contrast to previous reports, COX-2
overexpression was found to be an independent prognostic
factor for better survival in pancreatic adenocarcinoma.
Methods
Patients
The study included 230 consecutive patients (103 women
and 127 men) undergoing a standard Whipple’s procedure
for adenocarcinoma with curative intent 1998 -2011 at
Oslo University Hospital, Rikshospitalet. The study was
approved by the Regional Committee for Medical and
Health Research Ethical for Southern Norway.
Standard demographic, clinicopathological, and tumour-
specific data were collected retrospectively from hospital
records. Overall survival data was obtained from the
Norwegian Population Registry, updated June 20, 2013.
Since all Norwegian inhabitants receive a unique personal
identification number, no patients were lost to follow-up
in the present study. Patients were followed until death or
censored after maximum five years (60 months). By the
end of the study 177 patients were dead. Median follow-up
for the remaining 53 patients was 62 months (interquartile
range 29 -119 months). Perioperative death (defined as
death within 30 days of operation) was included in the
analyses (four patients). Analysis excluding perioperative
death gave similar results. None of the patients received
preoperative chemotherapy or chemoradiotherapy. From
2008, adjuvant chemotherapy with 5-fluororuracil was
recommended for eligible patients operated for pancreatic
cancer. Thirty-nine percent of the patients (13 of 33) oper-
ated in this period received adjuvant chemotherapy
(5-FU-based in 11 patients, 2 patients received gemcitabine).
Histopathological evaluation of resection specimens
The resection specimens were examined according to a
standardized protocol as described previously [1,35]. Allregistered parameters of the prospectively collected data
base, including anatomic site of tumour origin, where
later reevaluated by slide review [1]. The histological
type of differentiation was evaluated and all tumours
were classified either as intestinal or pancreatobiliary
type [3,36]. In brief, pancreatobiliary tumours typically
have simple or branching glands and small solid nests of
cells surrounded by a desmoplastic stroma, and have
cuboideal to low columnar epithelium arranged in a sin-
gle layer and the nuclei are rounded but with marked
variation in size and shape from one cell to the next. In-
testinal tumours typically resembled colon cancer, have
tall and often pseudostratified columnar epithelium
with oval nuclei located in the more basal aspect of the
cytoplasm, and there may also often be presence of
mucin [36,37].
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue was sectioned
(3 μm), dried at 60°C, and processed in a Ventana Bench-
Mark Ultra machine (Ventana Medical Systems Inc. (Tucson
Arizona USA). Slides were incubated with monoclonal
anti-COX-2 antibodies (Thermo Fischer Scientific rabbit),
Universal Alkaline Phosphatase Red Detection Kit (Ultra
View 760-501) and αSMA (Dako M.0851), DAB (Ultra
View 760-500). Additional immunostaining on duplicates
of twenty slides was performed with monoclonal COX-2
mouse antibody Invitrogen (Camarillo, CA, USA). Slides
were counterstained with haematoxylin, fixed, mounted
and analyzed using an inverted light microscope (Olympus,
Center Valley, PA, USA).
Evaluation of COX-2 immunostaining
Immunohistochemistry was performed on whole tumour
slices, which were assessed without prior knowledge of
the clinical and pathological parameters. In each section,
five different representative high-power fields (100×)
with tumour infiltration were selected and examined by
light microscopy. The intensity of staining was estimated
on a scale from 1-3 (1-negative, 2-moderate, 3-strong).
Cells were considered positive only if COX-2 intensity
was moderate or strong. The extent of the immunola-
beling was assessed as the percentage of positively
stained tumour cells and was expressed on the scale
from 1-3 where 1 represented less than 10% cells stained,
2 represented 10-50% and 3 over 50%. Since COX-2 dem-
onstrated considerable heterogeneity within individual
cases, the final immunoscore was obtained as the average
of the numeric scores for five high-power fields of each
case considered positive in intensity scoring. Based on
histograms of the staining for all tumours, the optimal
cut-off value for discrimination between negative and
positive staining was found to be 1.4. Islets of Langer-
hans and mucosa of the duodenum were moderately to
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with no COX-2 expression, and served as internal con-
trols. Identical sections with omission of the primary
antibody were used as negative controls. To test the val-
idity of the Thermo antibody used for the study cohort,
we performed additional immunostaining with a different
monoclonal COX-2 mouse antibody, Invitrogen (Camarillo,
CA, USA), on duplicates of twenty pancreatic cancer slides
from the study cohort. The results were identical (Figure 1a
and e). As Thermo antibody was not suitable for western
blotting (producer recommendation), only the Invitrogen
antibody was subjected to analysis by western blotting.
The results showed a highly specific bond for COX-2
(Figure 1f).
Almost half of study specimens (44%) were evaluated
independently by two examiners (EP and AS) and kappa
interobserver was 0.73, indicating substantial agreement
(95% CI 0.6-0.9).
Statistical analysis
Associations between variables were examined using
Chi-square test, Fisher’s exact test and Mann-Whitney
test. Continuous variables were reported as median with
corresponding range or interquartile range (IQR). Un-
adjusted survival analysis was performed using the
Kaplan-Meier method, comparing curves using log-rank
test. Multivariable Cox regression analysis was used for
adjusted survival analysis. Possible interactions were eval-
uated by inclusion of an interaction term in the models.
For all tests, a two-sided p < 0.05 was considered statisti-
cally significant. Statistical analyses were performed in
SPSS 19 for Windows (SPSS Inc., Chicago, IL).
Results
The study cohort consisted of 230 patients consecutively
resected for adenocarcinomas originating from the am-
pulla (AC) (n = 62, 27%), distal bile duct (DBC) (n = 76,
33%), or pancreas (PC) (n = 92, 40%). Median age at time
of resection was similar for the three groups (67 years,
range 37-83; p = 0.463 Kruskal-Wallis). Overall 5-year
(actual) survival was 5% for PC, 16% for DBC, and 44%
for AC (p < 0.001).
COX-2 expression and prognosis in ampullary, distal bile
duct and pancreatic cancer
COX-2 staining was very similar in all three tumour
types, with a positivity rate of 71% in PC, 72% in DBC,
and 77% in AC. The COX-2 expression was detected in
the cytoplasm of cancer cells in all three types of adeno-
carcinoma. No COX-2 immunostaining was detected in
the stroma cells (Figure 1a,b, and e). The expression
pattern showed heterogeneity both among different tu-
mours and within the individual tumour, as areas with
moderate to strong staining coexisted with negativeareas within the same tumour (Figure 1c). Islet cells
expressed moderately to strong COX-2 staining in all cases
including those with no COX-2 expression in the tumour
(Figure 1d). Irrespective of tumour origin, overall patient
survival was more favourable in COX-2 positive than
COX-2 negative tumours (Figure 2a-c). This was particu-
larly prominent in AC (p = 0.011) and PC (p = 0.043)
whereas the same tendency was seen in DBC although not
reaching significance (p = 0.06). COX-2 expression varied
according to the type of histological differentiation. In
tumours with pancreatobiliary type of differentiation,
two thirds of the tumours were COX-2 positive irre-
spective of anatomical origin (67%, 69%, and 68% in AC,
DBC and PC, respectively). However there was no sig-
nificant difference in overall survival when comparing
COX-2 positive and negative tumours in this group
(Figure 2d-f ). All PC and DBC tumours with intestinal
type of differentiation were COX-2 positive whereas
84% of the intestinal AC tumours expressed COX-2.
The survival data of the intestinal AC tumours showed
a favourable prognosis for patients with tumours express-
ing COX-2 (p = 0.003) (Figure 2g-i).
Factors associated with prognosis in pancreatic
adenocarcinoma
COX-2 expression status was compared across clinical
parameters associated with survival in the subgroup
consisting of the 92 patients resected for pancreatic
adenocarcinoma. The median survival for patients with
COX-2 positive tumours was 18 months (95% CI 14-22)
as compared to 11 months (95% CI 9.6-12) for patients
with COX-2 negative tumours (p = 0.043). COX-2 positive
tumours were more likely associated with high degree of
differentiation (p = 0.002) and with intestinal type of dif-
ferentiation, although, the latter did not reach significance
(p = 0.099) (Table 1) probably due to the low number of
tumours of the intestinal differentiation type.
There was no association with COX-2 positivity and
R-status, lymph node ratio (LNR), lymph node status,
tumour diameter, T classification, and vascular or peri-
neural infiltration (Table 1). Since tumours expressing
COX-2 were significantly more likely to be highly differ-
entiated than COX-2 negative tumours, the joint effects
of COX-2 status and differentiation grade on survival
were assessed by Kaplan-Meier analysis, stratifying for
COX-2 status (positive vs. negative) and differentiation
grade (grade 1 and 2 vs. grade 3 and 4) (Figure 3a).
Patients whose tumours did not express COX-2 and
had a low differentiation grade (grade 3 and 4) had sig-
nificantly poorer survival than the other three groups
(p = 0.006).
In a previous report we found that LNR independently
predicted prognosis in a multivariate model for survival
Figure 1 COX-2 expression in tumour tissue from pancreatic cancer. a-d Double immunostaing with monoclonal anti-COX-2 antibody
(Thermo Fischer Scientific rabbit) and monoclonal anti-αSMA (Dako). COX-2 tumour positive cells (red colour), αSMA positive stromal cells (brown
colour). a magnification × 100, b magnification × 200, c Heterogeneity in COX-2 expression within pancreatic cancer tissue. Areas with moderate
to strong staining (thick arrow) coexist with COX-2 negative areas (thin arrow), (magnification x 100) d Moderately to strong COX-2 staining in islet cells
(thin arrow), pancreatic cancer negative for COX-2 staining, (magnification x 100). e Immunohistochemistry of COX-2 expression in tumour tissue from
pancreatic cancer. Immunostaining with monoclonal COX-2 mouse antibody Invitrogen (the same tumour as in a), magnification x 100. f Western blot
of COX-2 expression in the moderately differentiated pancreatic cancer cell lines BxPC3 and HPAFII known to overexpress COX-2, with and without
induction by interleukin 1 (Il-1), showed a specific bond for COX-2 (70 kDA) (monoclonal COX-2 mouse antibody Invitrogen).
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the joint effects of COX-2 status and LNR, and found that
patients with COX-2 negative tumours and LNR >0.2 had
significantly worst prognosis (p < 0.001) (Figure 3b).In a multivariate analysis model including COX-2
expression, LNR, tumour size, margin status, vascular
and perineural infiltration, COX-2 negative tumours
and LNR > 0.2 independently predicted poor prognosis
Figure 2 Overall survival analysis stratified by COX-2 expression. a Ampullary cancer (AC), b Distal bile duct cancer (DBC), c Pancreatic
cancer (PC). d-f Overall survival analysis for AC, DBC and PC with pancreatobiliary differentiation stratified by COX-2 expression. g-i Overall survival
analysis for AC, DBC and PC with intestinal differentiation stratified by COX-2 expression.
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Table 1 Clinicopathological variables in 92 consecutive pancreatoduodenectomies for pancreatic cancer stratified by
COX-2 status





≤ 20 mm 15 (16%) 3 (20%) 12 (80%)
> 20 mm 77 (84%) 24 (31%) 53 (69%) 0.54b
Lymph node metastasis
N0, n (%) 25 (27%) 5 (20%) 20 (80%)
N1, n (%) 67 (73%) 22 (33%) 45 (67%) 0.229
Lymph node ratio (LNR)c
≤ 0.2 54 (59%) 13 (24%) 41 (76%)
> 0.2 37 (41%) 13 (36%) 24 (65%) 0.251
Vascular invasion
No, n (%) 30 (33%) 12 (40%) 18(60%)
Yes, n (%) 62 (67%) 15 (24%) 47 (76%) 0.119
Perineural infiltration
No, n (%) 15 (16%) 3 (20%) 12 (80%)
Yes, n (%) 77 (84%) 24 (31%) 53 (69%) 0.54b
T classification
T1 3 (3%) 1 (33%) 2 (67%)
T2 6 (7%) 1 (17%) 5 (83%)
T3 83 (90%) 25 (30%) 58 (70%) 0.851b
R1 resection status, n (%)
R0, n (%) 40 (44%) 10 (25%) 30 (75%)
R1, n (%) 52 (56%) 17 (33%) 35 (67%) 0.422
Degree of differentiation
Grade I, II 53 (58%) 9 (17%) 44 (83%)
Grade III, IV 39 (42%) 18 (46%) 21 (54%) 0.002
Type of differentiation
Pancreaticobiliary, n (%) 84 (91%) 27 (32%) 57 (68%)
Intestinal, n (%) 8 (9%) 0 (0%) 8 (100%) 0.099b
PC, pancreatic adenocarcinoma.
aChi-square test, when not otherwise specified.
bFisher’s Exact Test.
cLNR assessment of 91 patients since in one specimen no lymph nodes were retrieved.
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COX-2 expression and differentiation grade (p = 0.002)
it was not possible to include differentiation grade in
the same model.
Only a minority of the patients received adjuvant
chemotherapy. Although the numbers are small, there
was no difference in survival between patients with
COX-2 positive and COX-2 negative tumours who re-
ceived adjuvant treatment.Discussion
There is a large body of epidemiological, clinical and
molecular evidence suggesting that COX-2 is implicated
in the oncogenesis and progression of gastrointestinal
malignancies, including adenocarcinomas derived from
pancreatic head structures. It has previously been shown
that COX-2 is upregulated in subsets of pancreatic, am-
pullary and distal bile duct adenocarcinomas although
the proportion of upregulated tumours varies in the
a b
Figure 3 Overall survival analysis for patients with pancreatic cancer stratified by COX-2 expression and a degree of differentiation,
b Lymph node ratio (LNR).
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importance of COX-2 expression in these tumours is
conflicting. In pancreatic adenocarcinoma, two studies
reported that COX-2 expressing tumours were associ-
ated with worse overall prognosis [19,21] whereas other
studies have suggested a trend towards better prognosis
for tumours with high COX-2 expression [22] or no as-
sociation at all [39-41]. The present data on pancreatic,
distal bile duct and ampullary adenocarcinomas indi-
cates a more favourable overall survival for patients with
COX-2 expressing tumours.
In periampullary and pancreatic head tumours, we
have previously shown that histologic subtyping of these
tumours into intestinal and pancreatobiliary types corre-
lates with cell-type specific markers [36] and prognosis
[3,37]. As COX-2 is thought to be expressed in epithelial
cells throughout the gastrointestinal tract [5,12,42] itTable 2 Multivariate Cox regression analysis of
histopathologic factors in 92 patients with pancreatic
cancer
p-value HR 95% CI
R-status (R1vs R0) 0.87 1.038 0.65 - 1.65
Vascular invasion
(Involved vs non- involved)
0.455 1.208 0.74 - 1.98
Perineural infiltration
(Involved vs non- involved)
0.359 1.369 0.70 - 2.68
Tumour size
(> 20 mm vs ≤ 20 mm)
0.315 1.434 0.71 - 2.90
COX-2 expression
(Negative vs Positive)
0.047 1.642 1.01 - 2.68
Lymph node ratio
(LNR) (> 0.2 vs ≤ 0. 2)
0.032 1.757 1.05 - 2.94was of particular interest to examine whether there are
differences in COX-2 expression in the intestinal and
pancreatobiliary subtypes. Of note, most intestinal ampul-
lary tumours (84%) were COX-2 positive, and in particu-
lar, all intestinal pancreatic and distal bile duct tumours
were COX-2 positive. Patients with ampullary cancers of
the intestinal subtype, which expressed COX-2, had a
favourable prognosis with a 5-year actual survival of 60%.
Histopathologic type of differentiation combined with bio-
markers or gene expression profiles has recently attracted
interest as important factors for outcome as well as strati-
fication for adjuvant chemotherapy in ampullary adeno-
carcinoma [43,44].
The finding in the present study that COX-2 expres-
sion correlates with a favourable prognosis in pancreatic
cancer can be explained by the fact that there is a statis-
tically significant association between COX-2 positivity
and high degree of differentiation. More than 80% of tu-
mours with high differentiation grade showed overexpres-
sion of COX-2. This result is consistent with previous
observations from studies of cultured pancreatic cancer
cells and pancreatic cancer tissue. In cultured tumour cells
COX-2 expression was found to be restricted to moder-
ately and highly differentiated pancreatic cancer cell lines
[23,26,45]. In human pancreatic adenocarcinoma tissue,
well differentiated lesions expressed COX-2 to the highest
degree, whereas there was less expression of COX-2 in
moderately and poorly differentiated lesions [30]. In our
study, the subgroup of patients with COX-2 positive/well
differentiated tumours had a significantly better survival
compared to patients with COX-2 negative/poorly differ-
entiated tumours, whereas COX-2 positive/poor differen-
tiation and COX-2 negative/high differentiation formed
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presence of COX-2 expression in these tumours appears
to be a marker of favourable prognosis closely linked to
the degree of tumour differentiation. Consistent with the
latter the strong statistical association between COX-2
expression and differentiation grade precluded inclusion
of both variables in the same multivariable model for
survival.
The precise function of COX-2 in pancreatic cancer
development is not known. In the normal pancreas, only
islet cells always express COX-2 [24]. In transgenic mice
models, overexpression of COX-2 in normal pancreatic
ductal cells results in development of dysplastic changes
resembling IPMNs and PanINs [46,47] suggesting a pri-
mary role of pancreatic cell COX-2 overexpression in
the initiation of ductal adenocarcinoma. Recent evidence
suggests that this is an intrinsic role of pancreatic cells
independent of prostaglandins from the tumour micro-
environment [48]. These observations support the con-
cept that COX-2 overexpression might be a causal factor
in pancreatic cancer development. It has also been sug-
gested that pancreatic cancers that lack COX-2 (and
COX-1) depends on exogenic prostaglandins from stromal
fibroblasts for proliferation and other cancer-promoting
effects [49]. Since COX-2 overexpression is implicated in
tumour development, its expression in pancreatic cancer
was hypothesized to result in a poor patient prognosis
[19]. This hypothesis is difficult to reconcile with the ob-
servation that in fully developed tumours, COX-2 expres-
sion has been shown to be a function of differentiation
status, with highest expression in well differentiated
tumours [30]. In addition, it has been demonstrated
that COX-2 expression varies markedly throughout the
pathological process of pancreatic neoplasia. COX-2
expression increases in a stepwise manner with each
initial stage of neoplastic progression up to the PanIN
2 stage, whereas COX-2 expression was relatively lower in
invasive cancers [30].
Some of the discrepancies in results between our study
and the studies by Juuti et al [19] and Matsubayashi et al
[21] might be explained by methodological differences in
patient sampling and/or tumour immunohistochemistry
techniques. Since it is well known that it can be difficult
to determine the precise anatomical origin of tumours of
the pancreatic head, all cancers in the present series
were re-evaluated for correct sub-classification into am-
pullary, distal bile duct or pancreatic tumours. There are
also certain differences pertaining to the immunohisto-
chemistry protocols that differ in our study compared to
the studies by Juuti et al [19] and Matsubayashi et al
[21]. In the work of Juuti, more than 30 years old speci-
mens were included in the study cohort. It is known that
for immunohistochemical staining protocols aging of
fixed tumour tissue might interfere with staining [50].Not only aging of the waxed specimen itself, but also
variations in fixation protocols over time may result in
inadequate staining. This may partly explain the low fre-
quency of COX-2 staining (36%) in their data, compared
to 55-80% in most other reports [20,22,23,25,26,41,51].
Since COX-2 expression in pancreatic tumours often is
heterogeneous [24,29,30], the actual number of COX-2
positive tumours might be underestimated unless immu-
nohistochemistry is performed on whole slide sections
and assessed on multiple different high-power fields within
each tumour. In the study of Matsubayashi [21], assessment
of COX-2 staining was performed on tissue microarrays.
Although this method has many advantages, tissue micro-
arrays might not be the optimal method for assessment
of COX-2 staining even if two cores of tumour tissues
were studied from each tumour. This may partly ex-
plain the lower proportion of tumours expressing
COX-2 in some studies [19,21] and hence the differ-
ences in patient survival.
Conclusion
COX-2 is overexpressed in pancreatic cancer, ampullary
cancer and distal bile duct cancer and confers a survival
benefit in all three cancer types. The overexpression is
consistently linked to the histopathological type of differ-
entiation and to the degree of differentiation. In pancreatic
adenocarcinoma, COX-2 overexpression independently
predicts a favourable prognosis.
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